BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today announced that ADCETRIS™ (brentuximab vedotin) will be featured in multiple presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011, in San Diego, Calif.
